CA
NZ
UK
AU
IND
US
TMC the Metals Company Inc. filed a Form 8-K with the SEC on August 17, 2026, disclosing that the National Oceanic and Atmospheric Administration has published a Notice of Intent to prepare an Environmental Impact Statement for a deep seabed exploration license application submitted …
NVIDIA Corporation filed a Form 8-K with the SEC on August 17, 2026, disclosing a multi-year partnership with SB Energy Corp. and the execution of residual value guaranties capped at $105 billion related to a large-scale AI data center campus in Pike County, Ohio.
Corebridge Financial, Inc. filed a Form 8-K on August 17, 2026 to submit audited and unaudited financial statements of Equitable Holdings, Inc. and unaudited pro forma combined financial statements of New Equitable in connection with a planned merger announced on March 26, 2026.
BridgeBio Pharma, Inc. filed a Form 8-K on August 17, 2026, disclosing that selling stockholder KKR Genetic Disorder L.P. entered into an Underwriting Agreement on August 13, 2026, to offer 5,000,000 shares of BridgeBio common stock at $78.00 per share.
Evolution Metals & Technologies Corp. filed its quarterly report on Form 10-Q with the SEC for the period ended June 30, 2026, disclosing condensed consolidated financial statements and management discussion as of August 17, 2026.
Padmanabh P. Bhatt, Senior Vice President of IP and Chief Scientific Officer of Supernus Pharmaceuticals, Inc., filed a Form 4 on August 14, 2026, disclosing transactions in common stock on August 12, 2026, related to the vesting of Performance Share Units.
Jonathan Rubin, SVP and Chief Medical Officer of Supernus Pharmaceuticals, Inc., filed a Form 4 on August 14, 2026, disclosing transactions in common stock dated August 12, 2026, related to the vesting of Performance Share Units.
Jack A. Khattar, President and CEO of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), filed a Form 4 on August 14, 2026, reporting the vesting of Performance Share Units and a related tax withholding transaction dated August 12, 2026.
Yann Mazabraud, EVP and Head of International at Rhythm Pharmaceuticals, Inc., filed a Form 4 on August 14, 2026, disclosing a stock option exercise and the sale of common shares on August 12, 2026, all executed under a pre-established Rule 10b5-1 trading plan.
Jennifer Kayden Lee, Executive Vice President and Head of North America at Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), filed a Form 4 on August 14, 2026, reporting stock option exercises and a same-day sale of common stock executed on August 13, 2026.
Please wait processing your request...